Sugi Predict

Sugi Predict / Targets / LGR4

LGR4

Leucine-rich repeat-containing G-protein coupled receptor 4 · Q9BXB1 · LGR4 on Sugi Atlas →

860 patent compounds predicted against LGR4, 795 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL24515623 SCHEMBL24515623 1.00 1/20
SCHEMBL24516809 SCHEMBL24516809 1.00 1/20
SCHEMBL25642962 SCHEMBL25642962 1.00 1/20
SCHEMBL25646985 SCHEMBL25646985 1.00 1/20
SCHEMBL26613198 SCHEMBL26613198 1.00 1/20
SCHEMBL25642461 SCHEMBL25642461 0.85 1/20
SCHEMBL25642789 SCHEMBL25642789 0.82 1/20
SCHEMBL25642690 SCHEMBL25642690 0.81 1/20
SCHEMBL25642685 SCHEMBL25642685 0.79 1/20
SCHEMBL25642994 SCHEMBL25642994 0.79 1/20
SCHEMBL25642689 SCHEMBL25642689 0.75 1/20
SCHEMBL25647639 SCHEMBL25647639 0.74 1/20
SCHEMBL24516256 SCHEMBL24516256 0.73 1/20
SCHEMBL26613124 SCHEMBL26613124 0.73 1/20
SCHEMBL24516816 SCHEMBL24516816 0.71 1/20
SCHEMBL24516818 SCHEMBL24516818 0.71 1/20
SCHEMBL25647895 SCHEMBL25647895 0.71 1/20
SCHEMBL24515594 SCHEMBL24515594 0.71 1/20
SCHEMBL25642683 SCHEMBL25642683 0.71 1/20
SCHEMBL25642989 SCHEMBL25642989 0.71 1/20

Clinical trials — most relevant to LGR4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus. PHASE3COMPLETED
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Follicle-Stimulating Hormone (FSH) and the Onset of Puberty EARLY_PHASE1COMPLETED
Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins nanCOMPLETED
Inherited Reproductive Disorders nanRECRUITING
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies nanUNKNOWN
History of Polycystic Ovary Syndrome in First-degree Relatives nanCOMPLETED
Genetics of Rolandic Epilepsy nanCOMPLETED
Gut Microbiome in Patients With Polycystic Ovary Syndrome nanUNKNOWN
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment nanCOMPLETED
Study of Prostate Cancer in Black and White U.S. Veterans nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis nanRECRUITING
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization nanCOMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
International Genetic Obesity Registry nanRECRUITING
Adipogenic Capacity as a Mediator of Weight Gain nanUNKNOWN
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer nanUNKNOWN
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Hyperbaric Oxygen Therapy for Post Traumatic Stress Disorder nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LGR4 binder may also engage these)

ProteinNameSimilarity
F1MLX5 — 1.000 F1MLX5 →
A2ARI4 — 0.997 A2ARI4 →
Q9Z2H4 — 0.997 Q9Z2H4 →
B0BLW3 — 0.995 B0BLW3 →
P0DM44 — 0.993 P0DM44 →
D4AC13 — 0.988 D4AC13 →
F1MT22 — 0.987 F1MT22 →
Q9Z1P4 — 0.987 Q9Z1P4 →
F7D3V9 — 0.986 F7D3V9 →
E5DHB5 — 0.986 E5DHB5 →
O75473 — 0.983 O75473 →
Q80ZD8 — 0.979 Q80ZD8 →
Q8BGA3 — 0.979 Q8BGA3 →
D4A7P2 — 0.978 D4A7P2 →
Q80ZD7 — 0.977 Q80ZD7 →
Q8N7C0 — 0.977 Q8N7C0 →
E7FE13 — 0.977 E7FE13 →
Q66HV9 — 0.976 Q66HV9 →
Q9HBX8 — 0.976 Q9HBX8 →
O43300 — 0.976 O43300 →
Q96FE5 — 0.976 Q96FE5 →
Q5R6B1 — 0.975 Q5R6B1 →
A1A4H9 — 0.975 A1A4H9 →
Q86VH4 — 0.974 Q86VH4 →
A4IIW9 — 0.974 A4IIW9 →
Q3UVD5 — 0.974 Q3UVD5 →
A0N0X6 — 0.973 A0N0X6 →
Q86WK6 — 0.973 Q86WK6 →
Q5M8M9 — 0.973 Q5M8M9 →
Q9N008 — 0.973 Q9N008 →